bmiMD vs Found

Two ladders, both published

bmiMD sells on a ladder keyed to plan length. Each longer prepaid term buys a lower monthly rate, and within any chosen term the rate holds as the dose climbs. There is also a newer lower-dose product line on the same structure.

Found runs a ladder too. It has four plan lengths per drug, each cheaper per cycle than the last, with separate cash and insurance grids. The advertised rate is the twelve-month rung.

What both do well is publish the rungs. A reader can see what each term costs and do the arithmetic before handing over a card, rather than meeting the structure at checkout. A ladder is also a device designed to make the longest term look obviously correct, so read the rungs as what they are: a discount for accepting risk the provider would otherwise carry.

What leaving costs at each

bmiMD charges a non-refundable fee to cancel once intake has been approved. It is disclosed rather than hidden, and it is small next to a course of treatment. It also lands at the exact point a patient would want to change their mind.

Found publishes a specific refund policy for its membership fee, which is more than most of this field commits to in writing. Read that policy against the twelve-month plan before deciding, because the two terms interact.

bmiMD offers a counterweight at the other end. It describes the charge taken at checkout as an authorization hold, released without a charge if a provider declines the patient. That addresses a common grievance in this category: being billed before anyone has confirmed eligibility.

Which drug you want changes the arithmetic

Across this category tirzepatide usually costs more than semaglutide, and bmiMD's ladder follows that pattern.

Found's ladder prices tirzepatide above semaglutide on every rung.

So compare the two ladders drug by drug and rung by rung. Check which compound a figure belongs to before treating it as a verdict on either provider.

Only one of these offers an approved product

Found offers brand-name GLP-1s on a separate track from its compounded program: the Wegovy pen, the Wegovy pill and Zepbound at the manufacturer's price, with its membership charged on top. bmiMD publishes compounded products only.

A compounded preparation is made by a compounding pharmacy and has not been through the FDA approval process a brand-name GLP-1 has. Those are two different purchases, and most of the price gap between them is explaining itself.

Found's own pricing pages state different starting points for brand-name medication, and the gap is wide. That discrepancy is reported rather than resolved, because resolving it would mean picking one of the company's own numbers. Get a brand-name figure in writing for your own situation.

How much each tells you about itself

bmiMD discloses that it is operated by Medccm Inc. A meaningful share of telehealth GLP-1 brands are marketing names attached to an entity a customer cannot identify, which leaves a patient nowhere to go past customer service. bmiMD also maintains a public Trustpilot profile, which is a place to read complaints rather than a rating worth endorsing.

Found displays a LegitScript seal, which is a published claim. A seal on a page establishes that a seal is published, not who holds the underlying certificate, and it is not converted into one here.

Neither names the pharmacy that compounds the medication. Found stops at the 503A licensing class, which is a category rather than an identity. On the disclosure that matters most for a compounded product, both fall short.

So which one

It depends on which of these matters more to you. If you want a brand-name, FDA-approved option available behind the same account, only Found offers one.

If you want the checkout hold released when a provider declines you, bmiMD spells that out. Weigh its cancellation fee honestly against Found's published refund policy — that pairing, not the headline figures, is the real trade.